Pharmacology of adenosine A2A receptors

https://doi.org/10.1016/S0165-6147(96)80010-1Get rights and content

Abstract

Adenosine A2A receptors, which have been cloned from several mammalian species, are activated by physiological concentrations of adenosine to stimulate the formation of cAMP and other mediators. The A2A receptors are found on neutrophil leukocytes, platelets, blood vessels and, very abundantly, on some cells in the CNS. In the caudate nucleus they coexist with dopamine D2 receptors, and stimulation of A2A receptors causes a decrease in D2 receptor-mediated neurotransmission Thus, drugs that act on A2A receptors can be used to modify dopaminergic neurotransmission known to be important in neurological and psychiatric disorders. In this review, Ennio Ongini and Bertil Fredholm describe how recently developed potent and selective A2A receptor antagonists can be used to delineate the physiological and pathological processes regulated by A2A receptors. Results from in vitro and in vivo pharmacology studies strengthen the notion that A2A receptors are an interesting target for drug development.

References (42)

  • J. Fastbom et al.

    Brain Res.

    (1990)
  • A. Green et al.

    J. Biol. Chem.

    (1990)
  • M. Adami et al.

    Eur. J. Pharmacol.

    (1995)
  • M.P. Abbracchio et al.

    Eur. J. Pharmacol. Mol. Pharmacol. Sect.

    (1992)
  • H. Nonaka

    Eur. J. Pharmacol.

    (1994)
  • M.R. Del Giudice

    Eur. J. Med. Chem.

    (1996)
  • P.G. Baraldi

    Bioorg. Med. Chem. Lett.

    (1994)
  • J. Kim et al.

    J. Biol. Chem.

    (1995)
  • Y. Zhang et al.

    Biochem. Pharmacol.

    (1994)
  • B.B. Fredholm

    Pharmacol. Rev.

    (1994)
  • M.A. Jacobson
  • M.E. Olah et al.

    Annu. Rev. Pharmacol. Toxicol.

    (1995)
  • K.A. Jacobson et al.

    J. Med. Chem.

    (1992)
  • M.G. Collis et al.

    Trends Pharmacol. Sci.

    (1993)
  • P.G. Baraldi

    Curr. Med. Chem.

    (1995)
  • D. van Caiker et al.

    J. Neurochem.

    (1979)
  • C. Londos et al.

    Proc. Natl. Acad. Sci. U. S. A.

    (1980)
  • J.W. Daly
  • R.F. Bruns et al.

    Mol. Pharmacol.

    (1986)
  • S. Braun et al.

    Biochemistry

    (1979)
  • C. Nanoff et al.

    Mol. Pharmacol.

    (1991)
  • Cited by (308)

    • The adenosine A (2A) receptor antagonist SCH58261 protects photoreceptors by inhibiting microglial activation and the inflammatory response

      2022, International Immunopharmacology
      Citation Excerpt :

      It was hypothesized that early regulation of adenosine receptors could delay or prevent photoreceptor degradation, and 1,2 days after injury was considered as the time point for early adenosine receptor intervention [15]. SCH58261 is a potent and selective competitive A2AR antagonist with a stable chemical structure [16]. SCH58261 has high affinity for human A2AR and is the most potent antagonist binding to human A2AR among several common A2AR antagonists, while SCH58261 has good bioavailability [17].

    View all citing articles on Scopus
    View full text